January 2026 Research Update

This month, the clearest pattern is that complement-blocking treatment in aHUS is being studied not only as "on or off," but as something that can sometimes be adjusted, paused, or switched with careful follow-up. A UK prospective study of eculizumab withdrawal found that relapse happened in a minority of participants, and only among those with identified complement dysregulation, with quick restart of eculizumab reported when relapse was detected. Smaller studies and case reports added examples of drug-level monitoring for ravulizumab and "rescue" switching to crovalimab after limited response to ravulizumab, showing how researchers are trying to tailor complement inhibition to individual situations. [1] [2] [3]

In the SETS aHUS study, 4 of 28 participants relapsed after stopping eculizumab during a 2-year follow-up, and 1 participant met a predefined harm outcome. Relapses were reported only in people with identifiable complement dysregulation, and the study reported that restarting eculizumab within 24 hours was feasible as part of the monitoring plan. This helps sharpen the idea that relapse risk after stopping may be concentrated in specific biological subgroups, although the study excluded some higher-risk patients and did not compare against a randomized continuation group. [1]

In a small pediatric cohort in remission, ravulizumab levels were consistently above a target trough level and complement activity stayed strongly suppressed, even in some children on a modified maintenance approach. The study reported similar safety event rates between standard and modified regimens, with lower drug costs in the modified group, but the sample was only 9 children and treatment was not randomly assigned. This adds an early signal that drug-level and complement-activity monitoring might support more individualized maintenance schedules in some settings. [2]

A separate modeling study tested whether a published eculizumab blood-level model could predict future trough concentrations well enough to support dose adjustment decisions. Using retrospective monitoring data from patients with PNH and aHUS, the authors reported acceptable prediction performance and that the model would lead to correct dosing decisions in most analyses (over 80%). This is not a clinical outcomes study, but it supports the practical feasibility of using measured drug levels plus a model to estimate whether blood levels are likely to stay in range. [4]

One case report described a person with genetic complement-mediated thrombotic microangiopathy who did not respond as expected to ravulizumab and plasma exchange, and then improved quickly in hemolysis after switching to crovalimab (another C5 blocker that binds C5 differently). Kidney recovery was slower, with improvement reported over months and continued gains over about a year. Because this is a single patient, it cannot show how often this approach works, but it illustrates why switching between complement inhibitors is being explored when response is incomplete. [3]

For patients and caregivers, this month adds a more concrete picture of how researchers are trying to personalize complement treatment in aHUS: when it might be possible to stop with close monitoring, how relapse risk may differ between people, and how blood-level monitoring could support maintenance decisions. The strongest new human evidence here is the prospective withdrawal study, which suggests relapses after stopping happened in a minority and were seen in those with identifiable complement dysregulation in that selected group. What remains uncertain is how these findings apply to people who were not included in the trial (for example, higher-risk groups), and whether monitoring-based dose changes improve long-term outcomes compared with standard care. These results mainly add understanding and structure for future care models, rather than proving a single best approach for everyone right now. [1] [2] [4] [3]

This month brought a clearer real-world signal about how to lower the risk of invasive meningococcal disease for people receiving long-term terminal complement inhibitors like eculizumab or ravulizumab. In European registry data, combined protection (vaccination plus continuous antibiotic prophylaxis) was linked with fewer meningococcal infections than using vaccination alone or antibiotics alone, after accounting for reported antibiotic adherence. The same report also highlighted practical gaps, such as missed booster doses and nonadherence to antibiotics, which can matter because these infections are rare but serious. [5]

Across 123 people categorized as having an implemented protection strategy, 1 invasive meningococcal infection occurred in the combined-protection group compared with 9 infections in the single-protection group. The study also reported that antibiotic noncompliance occurred in about one quarter of patients, and antibiotic resistance was documented in 3 infection cases. Because the number of infections was small and the study was observational, it cannot fully separate the effects of the protection strategy from differences between patients, but it strengthens the real-world evidence that using both approaches together may reduce risk compared with either alone. [5]

For people living with aHUS who use C5 inhibitors, this study adds real-world context to a familiar concern: meningococcal infections can occur despite protection efforts, and the protection plan depends on both the chosen strategy and how consistently it is followed. The results may matter now because they compare approaches already used in routine care, but they do not prove a single best strategy for every person since the data were not from a randomized trial and infections were uncommon. What became clearer is the size and direction of the difference observed in this registry setting, alongside the reminder that booster coverage and antibiotic adherence are common weak points that research is trying to measure more accurately. [5]

This month included several single-patient reports showing how aHUS or related complement-driven thrombotic microangiopathy can appear in very different real-life contexts, often after a triggering event. Across these cases, complement activation markers and blood test patterns helped support the diagnosis, and complement blockade with eculizumab was frequently followed by improved blood counts, while kidney outcomes varied widely. Because case reports describe individual experiences, they are most useful for illustrating possibilities and warning signs rather than predicting what will happen for most people. [6] [7] [8] [9] [10]

Several triggers were highlighted: severe infection (including septic shock), postpartum hemorrhage, a post-abortion infection, and mechanical stress from an artificial heart valve with dysfunction. In these reports, eculizumab was associated with rapid improvement in hemolysis or other blood markers in the infection-related and valve-related cases, while the postpartum case reported a good hematologic response despite severe kidney injury findings on imaging. Another report described recovery after therapeutic plasma exchange when eculizumab was not available, underscoring that access and timing can shape real-world care paths. [9] [7] [8] [6]

One transplant and pregnancy case showed a different angle: a woman with genetically confirmed complement-mediated thrombotic microangiopathy had a kidney transplant and later completed a term pregnancy without complement inhibition, with stable graft function reported through postpartum follow-up. This does not establish that pregnancy without complement blockade is broadly safe in similar conditions, but it shows that outcomes can be favorable in carefully managed individual situations. It also reinforces that genetics, transplant status, and pregnancy can intersect in complex ways that researchers are still trying to map. [10]

For patients and caregivers, these reports expand the list of real-world scenarios in which aHUS may be considered, including infections and pregnancy-related complications, and they show that blood-related recovery and kidney recovery may not move in lockstep. The evidence level is early because these are individual cases, so they mainly add awareness and help researchers recognize patterns and diagnostic clues rather than changing standard approaches. What remains uncertain is how often these triggers lead to aHUS, and which features best predict kidney recovery versus persistent kidney damage in each setting. Still, these cases provide concrete examples of how varied aHUS presentations can be, and why diagnosis can be challenging during complex medical events. [6] [7] [8] [9] [10]

Laboratory and early mechanistic work this month reinforced a consistent idea: in aHUS, over-activity of the alternative complement pathway can directly injure blood vessel lining and promote clot-like platelet buildup, and blocking the pathway can prevent these changes in experimental systems. One study using endothelial cell models exposed to patient sera found that blocking the alternative pathway, blocking C3, or blocking C5 each prevented abnormal complement activation and platelet aggregation on the cell surface. A separate mouse study suggested a potential strategy to shut down the alternative pathway by altering where and how a key protein (factor D) is produced, preventing disease in mouse models. [11] [12]

In the endothelial cell work, sera from people with aHUS could trigger C3 buildup, formation of the terminal complement complex (C5b-9), and large platelet aggregates on activated endothelial cells. These effects were prevented by iptacopan (an alternative pathway blocker), pegcetacoplan (a C3 blocker), and eculizumab (a C5 blocker), with similar patterns seen in both general and kidney-specific endothelial cells. This supports the idea that alternative pathway activation can be a central upstream problem even when a specific genetic variant is not the focus, while also remaining laboratory evidence rather than a clinical proof of benefit. [11]

In mice, forcing the liver to produce the mature form of factor D depleted factor B in the blood and essentially switched off alternative pathway activity, and this prevented disease in murine models of aHUS and C3 glomerulopathy. The authors also showed cell experiments suggesting that local production of complement proteins and regulation by MASP3 may be important for keeping the system from activating in the wrong place. This is early, preclinical work, but it provides a clearer map of possible future ways to control alternative pathway activation beyond C5 blockade. [12]

One additional case report linked severe infection with intense alternative pathway activation driven by C3 nephritic factor (C3NeF), with recovery after eculizumab and infection control and no relapse reported over more than 2 years. The report also tracked C3d on red blood cells as a marker that fell after treatment, suggesting one way complement activity might be monitored in similar rare situations. As a single case, this mainly supports the biological plausibility of infection plus complement overdrive acting together, not a general rule for most patients with aHUS. [13]

For patients, this theme mainly matters as research that helps explain why complement-blocking medicines can work, and why different points in the complement pathway (C3, the alternative pathway, or C5) are being explored. The endothelial cell and mouse studies do not predict how well any specific strategy will work in people, but they make the disease story more coherent: alternative pathway over-activation can set off vessel injury and platelet buildup, and blocking the pathway can prevent these steps in experimental settings. What remains uncertain is which patients would benefit most from upstream blockade in real life, and how to translate these laboratory signals into safe, tested treatments. The case report adds a real-world example consistent with this biology, but it is too rare to guide expectations for most families. [11] [12] [13]